Sarepta Therapeutics, Inc. (SRPT) Stock Forecast
SRPT analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.25 / 5 from 24 analysts
- Price target
- $21.64 average of analyst targets
- Upside to target
- +26.5% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $0.17
- 52-week range
- $14.86 – $24.45
SRPT analyst ratings
24 analystsNumber of analysts at each rating.
SRPT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SRPT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.36 | −$0.06 | $1.06 | −$0.13 | +374.9% | 10 |
| Current fiscal year (2026) | $4.32 | $2.88 | $5.90 | −$5.05 | +185.6% | 10 |
| Next fiscal year (2027) | $2.45 | $0.53 | $4.79 | $4.32 | −43.3% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SRPT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $350.8M | $322.4M | $392.2M | −12.2% | 19 |
| Current fiscal year (2026) | $1.83B | $1.78B | $1.92B | −16.6% | 20 |
| Next fiscal year (2027) | $1.38B | $858.4M | $1.77B | −24.7% | 19 |
SRPT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SRPT revenue: reported and forecast
SRPT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.48 | $0.39 | $0.42 | $0.37 | $0.36 | −26.3% | 0 up · 1 down |
| Current fiscal year (2026) | $4.79 | $4.39 | $4.44 | $4.34 | $4.32 | −9.7% | 0 up · 1 down |
| Next fiscal year (2027) | $2.45 | $2.57 | $2.57 | $2.41 | $2.45 | +0.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SRPT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SRPT beat in 8 of 12.
What analysts expect from SRPT
24 analysts cover Sarepta Therapeutics; their consensus rating is hold (3.25 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.64, 26.5% above the latest close of $17.10. Analysts expect earnings of $4.32 per share for 2026, +185.6% from a year earlier. For 2027 the average estimate is $2.45 per share on revenue of $1.4 billion. Sarepta Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: SRPT income statement, SRPT key metrics, SRPT chart. See the SRPT stock overview for the latest quote and news.
SRPT forecast FAQ
What is Sarepta Therapeutics's price target?
The average analyst price target for Sarepta Therapeutics is $21.64, 26.5% above the latest close of $17.10.
Is Sarepta Therapeutics a buy, hold or sell?
Of 24 analysts covering Sarepta Therapeutics, 7 rate it a strong buy, 0 a buy, 12 a hold, 2 a sell and 3 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Sarepta Therapeutics's EPS forecast?
Analysts forecast $4.32 per share for 2026 (range $2.88 to $5.90); for 2027 the estimate is $2.45.
What is Sarepta Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $1.8 billion, growth of −16.6%; for 2027 it is $1.4 billion.
When does Sarepta Therapeutics report earnings?
Sarepta Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026; the EPS estimate is $0.17.
Does Sarepta Therapeutics usually beat earnings estimates?
Sarepta Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.